Gastric cancer (GC) is the third leading cause of cancer-related death worldwide, with a median overall survival limited to 1 year for advanced disease. A significant fraction of GC is due to aberrant HGF/MET axis signaling, most commonly due to MET receptor gene amplification. However, no effective MET-targeted therapies are currently available, with resistance frequently emerging rapidly, following an initial response. The development of additional, alternative approaches to effectively inhibit MET and other RTKs is therefore a necessity for a cure to be found. We recently identified a number of novel soluble decoy RTKs isoforms (sdRTKs), generated by an alternative splicing/intronic polyadenylation (IPA) mechanism, which can act as potent natural inhibitors of RTK signaling. We developed an antisense-based method to specifically and effectively induce IPA usage and sdRTKs expression in vitro and in vivo. These compounds identify a new class of drugs that carry the advantage of simultaneously knocking down the pathological targets while introducing natural dominant-negative isoforms, thus greatly increasing their efficacy. We will apply this antisense-based approach to promote IPA and stimulate the expression of dominant-negative, endogenous soluble decoy MET inhibitory variants (sdMET), normally expressed at low levels. sdMETs encode the extracellular ligand-binding and dimerization domains, but lack the transmembrane and the intracellular kinase domains. We hypothesize that sdMET-inducing compounds suppress HGF/MET signaling by a three fold-mechanism: A) direct removal of full-length MET receptor mRNAs, B) binding and sequestration of MET ligand (HGF), and C) non- productive hetero-dimerization with residual MET receptors. We further posit that, as the resulting products are secreted from targeted cells, they affect signaling in both targeted and neighboring cells alike and interfere with paracrine and autocrine loops, thus wielding an amplified effect. Since the mechanism of action is different from that of current therapies, this strategy should be effective in all tumors that rely on HGF/MET signaling, including relapsing ones. To this end, we will pursue the following specific aims: 1) Identification and characterization of effective inhibitory sdMET splicing variants. 2) Reprogramming of MET splicing/polyadenylation in gastric cancer cells by antisense-based splicing redirection compounds that induce IPA. 3) Assessment of the therapeutic potential of sdMET-inducing antisense oligonucleotides in multiple gastric cancer models, in vitro and in vivo. These results will be important for the development of powerful novel investigative tools and therapeutic approaches in any cancer type where the HGF/MET signaling axis plays a determinant role. The findings emerging from this study will be broadly translatable to disease dependent on other RTKs and oncogenes, in gastric cancer and other tumors. Analogous compounds can in fact be similarly designed to directly target other RTKs or other targets responsible for drug-resistance and pathological signaling, or to overcome various mechanisms of resistance.

Public Health Relevance

A key aspect of tumorigenesis in a broad range of human cancers is the activation of Receptor Tyrosine Kinases signaling pathways. In gastric cancer, a large fraction of tumors is associated to the oncogenic HGF/MET axis signaling. While targeted MET tyrosine kinase inhibitors and neutralizing antibodies have entered clinical trials, their effectiveness in patients have been very limited, due to poor response rates and failure to meet primary end-point objective and/or to the rapid acquisition of resistance to the drug. As a consequence, gastric cancer patient with MET-dependent tumors continue to suffer high mortality rates because effective MET-targeted therapies remain unavailable. We propose to develop a novel approach for the treatment of MET-dependent tumors. Our alternative strategy is centered on the rational design of antisense compounds that re-direct MET pre-mRNA splicing, forcing cancer cells to express naturally occurring inhibitory dominant-negative soluble decoy MET variants, in place of the oncogenic MET full-length isoforms.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA219689-04
Application #
10062886
Study Section
Drug Discovery and Molecular Pharmacology Study Section (DMP)
Program Officer
Forry, Suzanne L
Project Start
2017-12-08
Project End
2023-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
4
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Rutgers University
Department
Biology
Type
Schools of Pharmacy
DUNS #
001912864
City
Piscataway
State
NJ
Country
United States
Zip Code
08854